Publications by authors named "L Vertechy"
Background: The utilization of poly-ADP-ribose polymerase (PARP) inhibitors (PARPi) as a first-line maintenance therapy for advanced ovarian cancer has increased significantly, with ∼80% of patients potentially eligible. This expansion has led to a rise in the population experiencing platinum-sensitive recurrence, yet data on first recurrence during PARPi are limited. This real-world study from a high-volume referral center aims to elucidate recurrence rates, disease distribution, and treatment modalities at the time of progression in PARPi-treated patients.
View Article and Find Full Text PDFIn the era of single and combination maintenance therapies as well as platinum and Poly (ADP-ribose) polymerase inhibitors (PARPi) resistance, the choice of subsequent treatments following first-line platinum-based chemotherapy in recurrent ovarian cancer (ROC) patients has become increasingly complex. Within the ovarian cancer treatment algorithm, particularly in the emerging context of PARPi resistance, the role of trabectedin, in combination with pegylated liposomal doxorubicin (PLD) still preserves its significance. This paper offers valuable insights into the multifaceted role and mechanism of action of trabectedin in ROC.
View Article and Find Full Text PDFIntroduction: Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting.
Areas Covered: Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed.
Article Synopsis
- PLD-Trabectedin is an approved treatment for relapsed platinum-sensitive ovarian cancer, but its effectiveness after PARP inhibitor (PARPi) treatment hasn't been thoroughly investigated.
- A study compared outcomes of patients who had received PARPi (cases) to those who had not (controls), finding that those previously treated with PARPi had a shorter median progression-free survival (PFS) of 8 months compared to 11 months for controls.
- Despite the PFS difference, the tolerability of PLD-Trabectedin was similar across both groups, indicating it remains a well-tolerated treatment option even for patients who have already undergone PARPi therapy.
Objective: Poly (ADP-ribose) polymerase (PARP) inhibitor resistance is problematic in epithelial ovarian cancer management and sequencing strategies may be performed to overcome this issue. In this context, our study evaluated the role of non-platinum doublet pegylated liposomal doxorubicin/trabectedin in ovarian cancer platinum-sensitive patients who experienced disease progression under PARP inhibitor maintenance.
Methods: This case-control study includes patients with recurrent epithelial ovarian cancer treated between March 2016 and April 2021 who progressed under PARP inhibitor maintenance.